Our Leadership Team

Cliff Chau

Board Member
Partner, HOPU Investments

Cliff Chau joined HOPU Investments in 2012 and serves as Partner in charge of healthcare investments. In this role, he focuses on building a HOPU healthcare ecosystem and investing in biotech, medtech and innovative healthcare services companies.
Cliff brings a wealth of experience in investments, risk management, operations and sales & marketing to his approach to healthcare industry. His current portfolio companies include Ambrx Inc., a biopharmaceutical company headquartered in San Diego, Mevion Medical Systems, a proton therapy system company headquartered in Massachusetts and I-Mab Biopharma, a China-based global player in innovative biologics and he sits on the boards of Ambrx and Mevion. In the early stage of his career, Cliff was responsible for the sales and marketing of clinical and laboratory products of Beckman Instruments, Bio-Rad and Merck in China.
Prior to joining HOPU, Cliff was the Managing Director and Head of Finance Department of China Investments Corporation (CIC). He was a member of CIC’s risk management committee and an observer of investment committee. He also represented CIC sitting on the boards of CITIC Capital and China Jianyin Investment Limited. Before CIC, Cliff was a Partner of KPMG’s Transaction Services Practice, where he advised numerous cross-border transactions and was deeply involved with assisting companies to implement their China strategies. He worked at KPMG’s Beijing office and Los Angeles office.
Cliff also sits on the boards of Advisory Committee for the Quantitative Finance Program of The Chinese University of Hong Kong (CUHK), Sinopec Marketing Company, and The China Tea Company.
Cliff holds an MBA from State University of New York, a BSc. in Biochemistry from CUHK and a C.P.A. State of California.